The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

EDUCATION

Research Projects

Project: Understanding the role of MAIT cells in immune responses to glioblastoma

Corbett Group

Glioblastoma (GBM) is a type of cancer that develops from the glial cells in the brain. GBM is a fast-growing tumour with an extremely poor prognosis, with only 25% of patients surviving more than one year post diagnosis. With no effective treatment currently available, there is an unmet need to understand immune responses to GBM in the brain to develop cutting edge immunotherapies. 

This project examines the capacity of MAIT cells to respond to GBM, utilising a range of in vitro and in vivo cancer models and techniques including flow cytometry, tissue culture and mouse models. Through this project we seek to understand how MAIT cells respond to GBM, and their dependence on the antigen presenting molecule MR1.

By better understanding the role of MAIT cells in GBM models, this project hopes to inform the development of novel treatment strategies for GBM. Unlike conventional T cells, MAIT cells express a conserved TCR across the entire population, presenting the unique opportunity to develop universal cell-based therapy or MAIT cell modulating therapeutic interventions.
 

Contact project supervisor for further
information and application enquiries

Project Supervisor

Associate Professor Alexandra Corbett

Project Co-supervisor

Dr Alexander Barrow

Dr Hamish McWilliam

Project availability
PhD/MPhil
Master of Biomedical Science

Corbett Group

corbetta@unimelb.edu.au

1 vacancies

Themes
Cross Cutting Disciplines

The Corbett group is part of the MAIT cell programme headed by Prof. Jim McCluskey, which also includes the group of Dr Sidonia Eckle and Dr Zhenjun Chen.

Mucosal-associated invariant T cells (MAIT cells) are a recently described set of unconventional T cells restricted by the MHC-I related protein 1 (MR1). MAIT cells are found in most mammals, including humans and mice, and are the most conserved set of T cells across different species. The protective and/or pathological role of MAIT cells in infections and other conditions, such as cancer, is still emerging. In light of their high frequency in humans, their functional potency and MR1 being monomorphic, MAIT cells are considered to be promising therapeutic and vaccination targets.

We are international leaders in MAIT cell research, having made significant breakthrough discoveries in MAIT cell immunity. These include identifying the antigens recognised by MAIT cells (Kjer-Nielsen et al. Nature 2012, Corbett, Eckle, Birkinshaw, Liu et al. Nature 2014, 2 patents) and the associated development of tetramers to characterise MAIT cells (Patented) (Reantragoon, Corbett et al. JEM 2013) as well as the establishment of several mouse models of disease in order to understand the role MAIT cells play in protective and aberrant immunity (Chen et al. Mucosal Immunol 2017, Wang et al. Nature Comms 2018, Wang et al. Science Immunol 2020, Zhao et al. Nature Comms In Press).

We have weekly MAIT cell programme data meetings, and our groups collaborate closely on several projects. We also share lab and management resources as well as lab and office space. Students may also be interested in other projects in the MAIT cell programme (Chen group, Eckle group).

The Corbett group is interested in understanding the production of vitamin-based antigens which are recognised by MAIT cells, as well as the signals that drive MAIT cell functions in various infection and disease settings with the long-term goal of manipulating MAIT cells for clinical benefit (vaccination or immune therapy).

We currently have two student projects on offer. However, interested PhD candidates are welcome to contact us at any time to discuss additional projects.